A methodological review of randomised n-of-1 trials.
Clinical trials
Crossover
Placebo
n-of-1 trials
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
29
06
2023
accepted:
09
04
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
15
4
2024
Statut:
epublish
Résumé
n-of-1 trials are a type of crossover trial designed to optimise the evaluation of health technologies in individual patients. This trial design may be considered for the evaluation of health technologies in rare conditions where fewer patients are available to take part in research. This review describes the characteristics of randomised n-of-1 trials conducted over the span of 12 years, including how the n-of-1 design has been employed to study both rare and non-rare conditions. Databases and clinical trials registries were searched for articles including "n-of-1" in the title between 2011 and 2023. The reference lists of reviews identified by the searches were searched for any additional eligible articles. Randomised n-of-1 trials were selected for inclusion and data were extracted on a range of design, population, and analysis characteristics. Descriptive statistics were produced for all variables. We identified 74 studies meeting our eligibility criteria, 13 of which (17.6%) were conducted in rare conditions. They were conducted in a range of clinical areas with the most common being neurological conditions (n = 16, 21.6%). The median (Q1, Q3) number of participants randomised was 9 (4, 20) and 12 trials (16.2%) involved a single patient only. Forty-six (62.2%) trials evaluated pharmaceutical interventions and 49 (66.2%) trials were placebo controlled. Trials had a median (Q1, Q3) of six (4, 8) periods and 61 (82.4%) compared two health technologies. Fifty-seven (77.0%) trials incorporated blinding and 32 (43.2%) had a washout period. Forty-nine trials (66.2%) used patient-reported outcome measures (PROMs) to assess the primary outcome. Trials used a range of approaches to analysis and 48 (64.9%) combined data from multiple patients. The characteristics of the n-of-1 trials conducted in rare conditions were generally consistent with those in non-rare conditions. n-of-1 trials are still underused and the application of the n-of-1 design for the evaluation of health technologies for rare diseases has been particularly limited. We have summarised the characteristics of randomised n-of-1 trials in rare and non-rare conditions. We hope that it can inform researchers in the design of future n-of-1 studies. Further work is required to provide guidance on specific design considerations, implementation, and statistical analysis of these studies. Not applicable.
Sections du résumé
BACKGROUND
BACKGROUND
n-of-1 trials are a type of crossover trial designed to optimise the evaluation of health technologies in individual patients. This trial design may be considered for the evaluation of health technologies in rare conditions where fewer patients are available to take part in research. This review describes the characteristics of randomised n-of-1 trials conducted over the span of 12 years, including how the n-of-1 design has been employed to study both rare and non-rare conditions.
METHODS
METHODS
Databases and clinical trials registries were searched for articles including "n-of-1" in the title between 2011 and 2023. The reference lists of reviews identified by the searches were searched for any additional eligible articles. Randomised n-of-1 trials were selected for inclusion and data were extracted on a range of design, population, and analysis characteristics. Descriptive statistics were produced for all variables.
RESULTS
RESULTS
We identified 74 studies meeting our eligibility criteria, 13 of which (17.6%) were conducted in rare conditions. They were conducted in a range of clinical areas with the most common being neurological conditions (n = 16, 21.6%). The median (Q1, Q3) number of participants randomised was 9 (4, 20) and 12 trials (16.2%) involved a single patient only. Forty-six (62.2%) trials evaluated pharmaceutical interventions and 49 (66.2%) trials were placebo controlled. Trials had a median (Q1, Q3) of six (4, 8) periods and 61 (82.4%) compared two health technologies. Fifty-seven (77.0%) trials incorporated blinding and 32 (43.2%) had a washout period. Forty-nine trials (66.2%) used patient-reported outcome measures (PROMs) to assess the primary outcome. Trials used a range of approaches to analysis and 48 (64.9%) combined data from multiple patients. The characteristics of the n-of-1 trials conducted in rare conditions were generally consistent with those in non-rare conditions.
CONCLUSIONS
CONCLUSIONS
n-of-1 trials are still underused and the application of the n-of-1 design for the evaluation of health technologies for rare diseases has been particularly limited. We have summarised the characteristics of randomised n-of-1 trials in rare and non-rare conditions. We hope that it can inform researchers in the design of future n-of-1 studies. Further work is required to provide guidance on specific design considerations, implementation, and statistical analysis of these studies.
TRIAL REGISTRATION
BACKGROUND
Not applicable.
Identifiants
pubmed: 38622638
doi: 10.1186/s13063-024-08100-1
pii: 10.1186/s13063-024-08100-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
263Informations de copyright
© 2024. The Author(s).
Références
Guyatt G, Sackett D, Taylor DW, Ghong J, Roberts R, Pugsley S. Determining optimal therapy—randomized trials in individual patients. New England J Med. 1986;314(14):889–92.
doi: 10.1056/NEJM198604033141406
Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med. 2011;8(2):161–73.
doi: 10.2217/pme.11.7
pubmed: 21695041
pmcid: 3118090
Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. J Clin Epidemiol. 2010;63(12):1312–23.
doi: 10.1016/j.jclinepi.2010.04.020
pubmed: 20863658
pmcid: 2963698
Mirza R, Punja S, Vohra S, Guyatt G. The history and development of N-of-1 trials. J R Soc Med. 2017;110(8):330–40.
doi: 10.1177/0141076817721131
pubmed: 28776473
pmcid: 5546658
Gabler NB, Duan N, Vohra S, Kravitz RL. N-of-1 trials in the medical literature: a systematic review. Medical Care. 2011;49(8):761–8.
Punja S, Bukutu C, Shamseer L, Sampson M, Hartling L, Urichuk L, et al. N-of-1 trials are a tapestry of heterogeneity. J Clin Epidemiol. 2016;76:47–56.
doi: 10.1016/j.jclinepi.2016.03.023
pubmed: 27079847
Abrahamyan L, Feldman BM, Tomlinson G, Faughnan ME, Johnson SR, Diamond IR, et al. Alternative designs for clinical trials in rare diseases. In: American Journal of Medical Genetics Part C: Seminars in Medical Genetics. Wiley Online Library; 2016. (Vol. 172, No. 4, pp. 313–331).
Davidson KW, Silverstein M, Cheung K, Paluch RA, Epstein LH. Experimental Designs to Optimize Treatments for Individuals: Personalized N-of-1 Trials. JAMA Pediatr. 2021;175(4):404–9.
doi: 10.1001/jamapediatrics.2020.5801
pubmed: 33587109
pmcid: 8351788
Rare diseases [no date] European Commission Research and Innovation [Internet]. [cited 2022 Nov 1]. Available from: https://research-and-innovation.ec.europa.eu/research-area/health/rare-diseases_en .
Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J clin epidemiol. 2011;64(10):1085–94.
doi: 10.1016/j.jclinepi.2010.12.019
pubmed: 21530171
Müller AR, Brands MM, van de Ven PM, Roes KC, Cornel MC, van Karnebeek CD, et al. Systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders: the power of 1. Neurology. 2021;96(11):529–40.
doi: 10.1212/WNL.0000000000011597
pubmed: 33504638
pmcid: 8032375
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71.
doi: 10.1136/bmj.n71
Samuel JP, Wootton SH, Holder T, Molony D. A scoping review of randomized trials assessing the impact of n-of-1 trials on clinical outcomes. PLOS ONE. 2022;17(6):e0269387.
doi: 10.1371/journal.pone.0269387
pubmed: 35653405
pmcid: 9162303
Senn S. The analysis of continuous data from n-of-1 trials using paired cycles: a simple tutorial. Trials. 2024;25(1):128.
doi: 10.1186/s13063-024-07964-7
pubmed: 38365817
pmcid: 10870460
Kaplan HC, Opipari-Arrigan L, Yang J, Schmid CH, Schuler CL, Saeed SA, et al. Personalized Research on Diet in Ulcerative Colitis and Crohn’s Disease: A Series of N-of-1 Diet Trials. Am J Gastroenterol. 2022;117(6):902–17.
doi: 10.14309/ajg.0000000000001800
pubmed: 35442220
Schmid C, Yang J. Bayesian Models for N-of-1 Trials. Harv Data Sci Rev. 2022;(Special Issue 3).